Related Experiment Video

Updated: Aug 23, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

[Levosimendan in heart failure]

Laura Scelsi1, Carlo Campana, Stefano Ghio

  • 1Unità Cardiomiopatie, Scompenso cardiaco e Trapianto di Cuore, Divisione di Cardiologia, IRCCS Policlinico San Matteo, Pavia. emilio.corbellini@tin.it

Recenti Progressi in Medicina
|August 12, 2004
PubMed

Insights

Traditional inotropic agents for heart failure show increased mortality and limited benefits. Calcium-sensitizers like levosimendan offer a safer, more effective alternative, improving patient outcomes and ejection fraction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Traditional inotropic agents for heart failure are associated with increased mortality and significant side effects, limiting their clinical utility.
  • A new class of drugs, calcium-sensitizers, has been developed to improve heart failure treatment.
  • Levosimendan has demonstrated safety and efficacy in prior trials for various heart failure etiologies.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of levosimendan in patients with decompensated heart failure.
  • To assess the impact of levosimendan on clinical status and left ventricular ejection fraction.

Main Methods:

  • A study involving 26 patients with decompensated heart failure of diverse origins.
  • Treatment administered as a continuous 24-hour infusion of levosimendan.

Main Results:

  • Levosimendan administration led to improvements in the overall clinical status of patients.
  • A significant enhancement in left ventricular ejection fraction was observed post-treatment.
  • The study supports the positive impact of levosimendan in managing acute heart failure.

Conclusions:

  • Levosimendan represents a promising therapeutic option for decompensated heart failure.
  • The drug effectively improves cardiac function and clinical condition in heart failure patients.
  • Further research should explore long-term outcomes and broader applications of levosimendan.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...